OLD Category: signatures

Should a Multigene Signature be Used in all Luminal Early Breast Cancers

• Hajjaji N et al.,

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial

• Gluz O et al.,

Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group

• Eder T et al.,

Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

• Picornell AC et al.,

Effects of polarized macrophages on the in vitro gene expression after Co-Culture of human pluripotent stem cell-derived cardiomyocytes

• Wrona EA et al.,

Immune signature profiling identified prognostic factors for gastric cancer

• Yang W et al.,

Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma

• Stromnes IM et al.,

Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism

• Götzl JK et al.,

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

• Rozeman EA et al.,

An immunome perturbation is present in juvenile idiopathic arthritis patients who are in remission and will relapse upon anti-TNFα withdrawal

• Leong JY et al.,

Temporal Profile of Transporter mRNA Expression in the Brain after Traumatic Brain Injury in Developing Rats

• Adams SM et al.,

Lipid Deprivation Induces a Stable, Naive-to-Primed Intermediate State of Pluripotency in Human PSCs

• Cornacchia D et al.,